MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
26 de febrero de 2019 actualizado por: MedImmune LLC
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150.
The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.
Tipo de estudio
Intervencionista
Inscripción (Actual)
32
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87131
- Research Site
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Research Site
-
Houston, Texas, Estados Unidos, 77030
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Research Site
-
-
-
-
-
Marseille, Francia, 13273
- Research Site
-
Villejuif, Francia, 94805
- Research Site
-
-
-
-
-
Dublin 8, Irlanda
- Research Site
-
Galway, Irlanda
- Research Site
-
-
-
-
-
Leicester, Reino Unido, LE1 5WW
- Research Site
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Age ≥ 18 years
- Subjects with histologically confirmed relapsed or refractory DLBCL who have received at least 1 prior rituximab containing chemotherapy regimen but no more than 5 prior lines of therapy
- Eastern Cooperative Group (ECOG) performance status of 0 or 1
- Measurable disease by International Working Group (IWG) response criteria for lymphoma
- Adequate organ and marrow function
Exclusion Criteria:
- Previous immune-mediated therapy
- Subjects with prior ASCT or allogenic HCT. Subjects ineligible for available curative options after failing ASCT and have met the hematologic criteria are eligible to participate in this study. Subjects with prior allogenic HCT will be excluded.
- Documented current central nervous system involvement
3. Active or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: MEDI4736
|
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
|
|
Experimental: MEDI4736 and tremelimumab
|
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
|
|
Experimental: MEDI4736 and AZD9150
|
MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events
Periodo de tiempo: Screening through 90 days after the last dose of study medication
|
Screening through 90 days after the last dose of study medication
|
|
|
Number of subjects experiencing dose-limiting toxicities
Periodo de tiempo: First dose of study medications through 28 days after the administration of MEDI4736 or MEDI4736 and tremelimumab, 35 days after administration of MEDI4736 and AZD9150
|
Changes from baseline in laboratory parameters, vital signs, and ECGs
|
First dose of study medications through 28 days after the administration of MEDI4736 or MEDI4736 and tremelimumab, 35 days after administration of MEDI4736 and AZD9150
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Number of subjects who develop anti-drug antibodies (ADA)
Periodo de tiempo: Screening through 90 days after last dose of study medication
|
Screening through 90 days after last dose of study medication
|
|
Time to Response
Periodo de tiempo: Screening though 3 years after the last subject receives the first dose of study medication
|
Screening though 3 years after the last subject receives the first dose of study medication
|
|
Duration of Response
Periodo de tiempo: Screening though 3 years after the last subject receives the first dose of study medication
|
Screening though 3 years after the last subject receives the first dose of study medication
|
|
Progression Free survival
Periodo de tiempo: Screening though 3 years after the last subject receives the first dose of study medication
|
Screening though 3 years after the last subject receives the first dose of study medication
|
|
Time to progression
Periodo de tiempo: Screening though 3 years after the last subject receives the first dose of study medication
|
Screening though 3 years after the last subject receives the first dose of study medication
|
|
Event free survival
Periodo de tiempo: Screening though 3 years after the last subject receives the first dose of study medication
|
Screening though 3 years after the last subject receives the first dose of study medication
|
|
Overall survival
Periodo de tiempo: Screening though 3 years after the last subject receives the first dose of study medication
|
Screening though 3 years after the last subject receives the first dose of study medication
|
|
MEDI4736 Maximum Plasma Concentration (Cmax)
Periodo de tiempo: Measured at defined study visits from time of first dose through end of treatment
|
Measured at defined study visits from time of first dose through end of treatment
|
|
Tremelimumab Maximum Plasma Concentration (Cmax)
Periodo de tiempo: Measured at defined study visits from time of first dose through end of treatment
|
Measured at defined study visits from time of first dose through end of treatment
|
|
AZD9150 Maximum Plasma Concentration (Cmax)
Periodo de tiempo: Measured at defined study visits from time of first dose through end of treatment
|
Measured at defined study visits from time of first dose through end of treatment
|
|
MEDI4736 Minimum Plasma Concentration (Cmin)
Periodo de tiempo: Measured at defined study visits from time of first dose through end of treatment
|
Measured at defined study visits from time of first dose through end of treatment
|
|
Tremelimumab Minimum Plasma Concentration (Cmin)
Periodo de tiempo: Measured at defined study visits from time of first dose through end of treatment
|
Measured at defined study visits from time of first dose through end of treatment
|
|
AZD9150 Minimum Plasma Concentration (Cmin)
Periodo de tiempo: Measured at defined study visits from time of first dose through end of treatment
|
Measured at defined study visits from time of first dose through end of treatment
|
|
Individual MEDI4736 Concentrations
Periodo de tiempo: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)
|
Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)
|
|
Individual tremelimumab Concentrations
Periodo de tiempo: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)
|
Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)
|
|
Individual AZD9150 Concentrations
Periodo de tiempo: Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)
|
Measured at defined study visits from time of first dose through 90 days after the end of treatment (approximately 15 months)
|
|
Change from baseline of STAT3 RNA (signal transducer and activator of transcription)
Periodo de tiempo: Measured at defined study visits from time of first dose through 90 days after last dose (approximately 15 months)
|
Measured at defined study visits from time of first dose through 90 days after last dose (approximately 15 months)
|
|
Baseline PD-L1 protein expression within the tumor
Periodo de tiempo: Measured on tumor samples provided at screening
|
Measured on tumor samples provided at screening
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
13 de julio de 2016
Finalización primaria (Actual)
4 de febrero de 2019
Finalización del estudio (Actual)
4 de febrero de 2019
Fechas de registro del estudio
Enviado por primera vez
27 de agosto de 2015
Primero enviado que cumplió con los criterios de control de calidad
11 de septiembre de 2015
Publicado por primera vez (Estimar)
15 de septiembre de 2015
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
27 de febrero de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
26 de febrero de 2019
Última verificación
1 de febrero de 2019
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Enfermedades linfáticas
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Linfoma
- Linfoma de células B
- Linfoma de células B grandes, difuso
- Agentes antineoplásicos
- Agentes antineoplásicos inmunológicos
- Durvalumab
- Tremelimumab
Otros números de identificación del estudio
- D4190C00023
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Sí
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .